07:00 , May 21, 2001 |  BC Week In Review  |  Company News

Applied Genetics Inc., Elan deal

The companies formed a joint venture to develop and market Applied Genetics's Dimericine topical treatment, which contains a DNA repair enzyme that reverses UV-damaged DNA in skin. ELN will invest $4 million in Applied Genetics...
08:00 , Mar 26, 2001 |  BC Week In Review  |  Clinical News

Dimericine: Phase III

Applied Genetics published in The Lancet that in an international 30-patient, 1 year trial Dimericine reduced the annual rate of new cancers by 1.6 new cancers per year (30%, p=0.006) and the annual rate of...
07:00 , Aug 10, 1998 |  BC Week In Review  |  Company News

Applied Genetics Inc. Dermatics other research news

AGI Dermatics received two SBIR grants from the National Cancer Institute. The first is a $100,000 Phase I grant to develop a second generation version of the company's T4N5 liposomes, which are in Phase III...